Prostatype Genomics Stock

Prostatype Genomics ROIC

The Return on Invested Capital (ROIC) of Prostatype Genomics (PROGEN.ST) as of Aug 10, 2026 is -122.41 %. In the previous year, Return on Invested Capital (ROIC) was -114.02 % — a change of 7.36% (lower).

ROIC

-122.41 %

YoY

7.36%

Last updated:

Return on Invested Capital (ROIC) of Prostatype Genomics is 2026 -122.41 % . Return on Invested Capital (ROIC) of Prostatype Genomics was 2025 -114.02 % . It decreases by 7.36% lower compared to the previous year.
Access this data via the Eulerpool API

Prostatype Genomics Stock analysis

What does Prostatype Genomics do? Prostatype Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prostatype Genomics stock

Return on Invested Capital (ROIC) of Prostatype Genomics is -122.41 % in 2026.

Return on Invested Capital (ROIC) of Prostatype Genomics changed from -114.02 % to -122.41 %, representing a 7.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Prostatype Genomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

Profitability — Prostatype Genomics

All Key Metrics — Prostatype Genomics